Huizenga N A, de Lange P, Koper J W, Clayton R N, Farrell W E, van der Lely A J, Brinkmann A O, de Jong F H, Lamberts S W
Department of Internal Medicine III, Erasmus University Rotterdam, The Netherlands.
J Clin Endocrinol Metab. 1998 Mar;83(3):917-21. doi: 10.1210/jcem.83.3.4648.
Corticotropinomas are characterized by a relative resistance to the negative feedback action of cortisol on ACTH secretion. In this respect there is a similarity with the clinical syndrome of cortisol resistance. As cortisol resistance can be caused by genetic abnormalities in the glucocorticoid receptor (GR) gene, we investigated whether the insensitivity of corticotropinomas to cortisol is also caused by de novo mutations in the GR gene. We screened for the GR gene in leukocyte and tumor DNA from 22 patients with Cushing's disease for mutations using PCR/single strand conformation polymorphism analysis. In a previous study, we identified 5 polymorphisms in the GR gene in a normal population. These polymorphisms were used as markers for the possible occurrence of loss of heterozygosity (LOH) at the GR gene locus. Except for 1 silent point mutation, we did not identify novel mutations in the GR gene in leukocytes or corticotropinomas from these patients. Of the 22 patients, 18 were heterozygous for at least 1 of the polymorphisms. In 6 of these patients, LOH had occurred in the tumor DNA. Of 21 patients examined for LOH on chromosome 11q13, only 1, with a corticotroph carcinoma, showed allelic deletion. As controls we studied 28 pituitary tumors of other subtypes (11 clinically nonfunctioning, 8 prolactinomas, and 9 GH-producing adenomas) and found evidence for LOH in only 1 prolactinoma. In six patients LOH was found at the GR gene locus (chromosome 5) in DNA derived from adenoma cells. Our observations indicate for the first time that LOH at the GR gene locus is a relatively frequent phenomenon in pituitary adenomas of patients with Cushing's disease. This might explain the relative resistance of the adenoma cells to the inhibitory feedback action of cortisol on ACTH secretion. The specificity of the GR LOH to corticotropinomas supports this concept. Somatic mutations of the GR are not a frequent cause of relative cortisol resistance in these cells.
促肾上腺皮质激素瘤的特征是对皮质醇对促肾上腺皮质激素(ACTH)分泌的负反馈作用具有相对抗性。在这方面,它与皮质醇抵抗的临床综合征相似。由于皮质醇抵抗可能由糖皮质激素受体(GR)基因的遗传异常引起,我们研究了促肾上腺皮质激素瘤对皮质醇的不敏感性是否也由GR基因的新发突变引起。我们使用PCR/单链构象多态性分析,在22例库欣病患者的白细胞和肿瘤DNA中筛查GR基因的突变。在先前的一项研究中,我们在正常人群中鉴定出GR基因的5种多态性。这些多态性被用作GR基因位点可能发生杂合性缺失(LOH)的标记。除了1个沉默点突变外,我们在这些患者的白细胞或促肾上腺皮质激素瘤中未鉴定出GR基因的新突变。在22例患者中,18例至少对1种多态性是杂合的。在其中6例患者中,肿瘤DNA中发生了LOH。在21例检测11号染色体q13上LOH的患者中,只有1例促肾上腺皮质激素癌患者出现等位基因缺失。作为对照,我们研究了28例其他亚型的垂体肿瘤(11例临床无功能,8例催乳素瘤和9例生长激素分泌性腺瘤),仅在1例催乳素瘤中发现了LOH的证据。在6例患者的腺瘤细胞衍生的DNA中,在GR基因位点(5号染色体)发现了LOH。我们的观察首次表明,GR基因位点的LOH在库欣病患者的垂体腺瘤中是一种相对常见的现象。这可能解释了腺瘤细胞对皮质醇对ACTH分泌的抑制性反馈作用的相对抗性。GR LOH对促肾上腺皮质激素瘤的特异性支持了这一概念。GR的体细胞突变不是这些细胞中相对皮质醇抵抗的常见原因。